These five stocks are known for their generous dividend programs and robust business models. October often brings both opportunity and volatility to the stock market. For investors seeking stability and income, dividend growth stocks can offer a compelling option in this dynamic market. These companies typically have strong financials, steady cash flows, and business models resilient enough to support consistent dividend increases. Here are five top dividend growth stocks to consider this October. Spanning ...

Last week, AbbVie (ABBV) announced that a pivotal phase III study evaluating pipeline candidate tavapadon for treating early Parkinson's disease met the primary endpoint. The candidate was added to AbbVie's pipeline with the August 2024 acquisition of Cerevel Therapeutics, a neuroscience drugmaker, for around $8.7 billion. ABBV's Positive Parkinson's Study Data In the TEMPO-1 study, patients who received two fixed doses (5mg and 15mg) of once-daily tavapadon, a D1/D5 dopamine receptor partial agonist, for 2 ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about AbbVie (ABBV) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.AbbVie currently has an average brokerage re ...

These 15 dividend stocks can deliver stable passive income for life.Dividend stocks offer a path to steady passive income, but not all are created equal. The key to long-term success lies in dividend sustainability, not just high current yields.The payout ratio serves as a critical tool for assessing sustainability. This metric, representing the percentage of earnings distributed as dividends, reveals a company's ability to maintain and grow its dividend. A conservative ratio below 50% typically signals str ...

AbbVie (ABBV) announced positive top-line results from the pivotal phase III TEMPO-1 study which evaluated its recently acquired investigational drug tavapadon in adults with early Parkinson’s disease (PD).The study achieved its primary endpoint, patients who received two fixed doses (5mg and 15mg) of once-daily tavapadon for 26 weeks achieved statistically significant improvement in disease burden. This was measured using the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) ...

- Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression.- Biologics License Application (BLA) submission for accelerated approval is supported by data from the Phase 2 LUMINOSITY trial (M14-239). Review of the BLA will be conducted under FDA's Oncology Center of Excellence (OCE) Real-Time Oncology Review (RTOR) program. - There are currently no approved anti-cancer therapies specifica ...

Even the mighty Novo Nordisk can't hold a candle to its peer in this area.Pharmaceutical giant Novo Nordisk (NVO 1.20%) is a terrific stock for many reasons. The company continues to deliver excellent financial results thanks to a lineup of medicines with incredibly fast-growing sales. Its pipeline also continues to produce more gems.Novo Nordisk's stock market performance has been incredible in recent years. It's hard to find a better growth stock among similarly sized drugmakers. However, it isn't a parti ...

Tavapadon met the primary endpoint in the pivotal Phase 3, TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III combined score at week 26Trial also met key secondary endpoint, demonstrating statistically significant improvement from baseline in the MDS-UPDRS Part II scoreResults from the Phase 3 TEMPO-2 trial, studying tavapadon as a flexible-dose monotherapy, are expected by the end of 2024NORTH CHICAGO, Ill., Sept. 26, ...

GERMANY - 2024/03/03: In this photo illustration, the Bristol-Myers Squibb Company logo is seen ... [+] displayed on a tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesGiven its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – AbbVie stock . BMY stock trades at a much lower multiple of 2.2x revenues, versus 6.2x for ABBV. This can be attributed to the latter’s supe ...

In the latest market close, AbbVie (ABBV) reached $191.26, with a -1.16% movement compared to the previous day. The stock's performance was behind the S&P 500's daily loss of 0.19%. Meanwhile, the Dow experienced a drop of 0.7%, and the technology-dominated Nasdaq saw an increase of 0.04%.Coming into today, shares of the drugmaker had lost 1.23% in the past month. In that same time, the Medical sector lost 1.58%, while the S&P 500 gained 1.95%.The investment community will be paying close attention to the e ...